Immunosuppressed patients may be affected by a wide range of lymphoproliferative disorders (LPDs) ranging from self-limiting disorders to malignant lymphoid proliferations. These LPDs may be associated with systemic immune disorders, develop following organ transplantation or occur in the background of other forms of iatrogenic immunosuppression. Lymphotropic viruses, including Epstein-Barr virus (EBV) and human herpesvirus-8 (HHV8), have been associated with the pathogenesis of distinct LPDs. The resulting classification of this group of disorders is very complex and inconsistent, with several new and emerging entities. Consequently, the diagnosis of an LPD, especially in an immunosuppressed patient, and its subsequent clinical management usually represent an important pitfall in daily clinical and pathology work. Therefore, the aim of this review was to use the available literature to describe the clinicopathological features of the most important benign LPDs that may be diagnosed in the head and neck region of immunosuppressed patients. Original clinical and microscopic images were used to illustrate some of these entities.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jop.13204 | DOI Listing |
Front Immunol
January 2025
Alexander Silberman Institute of Life Science, The Hebrew University of Jerusalem, Jerusalem, Israel.
Maternal immunization is an important tool directed against a variety of infectious maladies in the offspring. A complementary, but less explored area is the use of maternal immunization in the prevention and treatment of childhood cancers. This in part stems from the lack of adequate experimental model systems.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
Introduction: Multiple myeloma (MM) is an uncontrolled plasma cell proliferation in the bone marrow, leading to immune dysregulation with impaired humoral immune responses. Conversely, cellular-based responses play a vital role in MM patients. However, the extent and duration of cellular-induced protection remain unclear to date.
View Article and Find Full Text PDFInt J Biol Sci
January 2025
Department of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Chemoresistance is an important factor in multiple myeloma (MM) relapse and overall survival. However, the mechanism underlying resistance remains unclear. In this study, we identified adenine nucleotide translocase 3 (ANT3) as a novel biomarker and therapeutic target for MM progression and resistance to the proteasome inhibitor bortezomib (BTZ).
View Article and Find Full Text PDFZhonghua Yan Ke Za Zhi
January 2025
Department of Ophthalmology, Qingyuan Hospital Affiliated to Guangzhou Medical University (Qingyuan People's Hospital), Qingyuan511518, China.
A 63-year-old male patient presented with a four-month history of vision loss in the left eye and blurred vision in the right eye, the cause of which was not immediately apparent. The patient was initially diagnosed with uveitis in both eyes at the Department of Ophthalmology. Subsequently, the patient was diagnosed as central nervous system lymphoma at the Department of Brain Medicine and initiated a systemic treatment.
View Article and Find Full Text PDFZhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Blood Disease Institute, Xuzhou Medical University,Xuzhou 221000, Jiangsu Province, China.
Objective: To harvest the primary Philadelphia chromosome-positive (Ph) cells of B-acute lymphoblastic leukemia (B-ALL) and to establish the B-ALL mouse model.
Methods: The plasmid carrying fusion gene was transferred into the bone marrow(BM) cells of C57BL/6J mice by retrovirus. Syngeneic mice irradiated with 9 Gy of Co γ-ray were injected with the transfected BM cells as the first generation (G1), and then the primary cells from the spleen and BM of the diseased mice were obtained and frozen.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!